GPC5与前列腺癌发生及预后的关系  

Relationship between GPC5 and occurrence and prognosis of prostate cancer

作　　者：刘晓昀[1] 成波[1] 谭波[1] 李曙光[1] 王刚[1] 贾仁峰[1] Liu Xiaoyun;Cheng Bo;Tan Bo;Li Shuguang;Wang Gang;Jia(Renfeng Department of Urology,Shengli Oilfield Central Hospital,Dongying 257034,China)

机构地区：[1]胜利油田中心医院泌尿外科,东营257034

出　　处：《国际泌尿系统杂志》2019年第1期13-16,共4页International Journal of Urology and Nephrology

摘　　要：目的探讨磷脂酰肌醇蛋白聚糖-5(GPC5)与前列腺癌发生及预后的关系。方法选取2013年2月至2015年5月在本院治疗的前列腺癌患者104例(病例组),同时选取良性前列腺增生患者89例作为对照组,采用免疫组化染色法检测GPC5蛋白表达,采用荧光定量PCR检测GPC5mRNA表达。同时选取高侵袭前列腺癌PC3系细胞、低侵袭LNCaP系细胞以及正常前列腺上皮细胞RWPE-1系细胞,采用westernblot检测GPC5蛋白表达。结果观察组GPC5mRNA相对表达为(0.64±0.15)和GPC5蛋白阳性表达率为34.62%,明显低于对照组(P<0.05);术前PSA≥4ng/mL、肿瘤分期为T3、Gleason评分≥8分患者GPC5蛋白阳性表达率分别为20.34%、19.44%和21.05%,明显低于术前PSA<4ng/mL、肿瘤分期为T2和Gleason评分<8分患者(P<0.05);GPC5蛋白阳性表达患者中位总生存时间为39.04个月,明显高于GPC5蛋白阴性表达患者(P<0.05);PC3细胞GPC5蛋白表达为(0.083±0.024),明显低于LNcaP和RWPE-1细胞(P<0.05);LNcaP细胞GPC5蛋白表达为(0.301±0.083),明显低于RWPE-1细胞(P<0.05)。结论前列腺癌组织GPC5蛋白及mRNA表达下调,与临床病理特征及预后有关,值得进一步研究。Objective To investigate the relationship between the expression of phosphatidylinositol-5 (GPC5) and the genesis and prognosis of prostate cancer. Methods From February 2013 to May 2015, 104 cases of prostate cancer in our hospital as the observation group were selected. And 89 cases of benign prostatic hyperplasia were selected as the control group. The expression of GPC5 protein was detected by immunohistochemical staining and the expression of GPC5 mRNA was detected by fluorescent quantitative PCR. Highly invasiveprostate cancer PC3 cell lines, low invasive prostate cancer LNCaP cell lines and normal prostate epithelial cell line RWPE-1 cells were selected. The expression of GPC5 protein was detected by Western blot. Results The relative expression of GPC5 mRNA and the GPC5 protein positive expression rate in the observation group were (0.64±0.15) and 34.62%, significantly lower than that of the control group (P<0.05). Preoperative PSA ≥4 ng/mL, tumor staging T3, Gleason score ≥8 in patients with GPC5 protein positive expression rates were 20.34%, 19.44% and 21.05%, significantly lower than the preoperative PSA<4 ng/mL staging, tumor staging T2 and Gleason score <8 patients (P<0.05). The median overall survival time of GPC5 positive patients was 39.04 months, significantly longer than that in patients with negative GPC5 protein expression (P<0.05). The expression of GPC5 protein in PC3 cells was (0.083±0.024), significantly lower than that in LNcaP and RWPE-1 cells (P<0.05). The expression of GPC5 protein in LNcaP cells was (0.301±0.083), significantly lower than that in RWPE-1 cells (P<0.05). Conclusions The expression of GPC5 mRNA and protein in prostate cancer is down regula-ted, which is related to clinicopathological features and prognosis, it is worthy of further study.

关 键 词：前列腺肿瘤 磷脂酰肌醇蛋白聚糖类 预后 

分 类 号：R737.25[医药卫生—肿瘤]